Poolbeg Pharma secures European patent grant for POLB 001 in cancer immunotherapy-induced CRS

Poolbeg Pharma (POLB)  has received formal notification from the European Patent Office (EPO) of its decision to grant a patent covering POLB 001 for the prevention of cancer immunotherapy-induced Cytokine Release Syndrome (CRS).

The European patent marks a significant milestone in Poolbeg's intellectual property strategy, providing protection across key European markets and representing the most commercially important grant secured to date within the company's cancer immunotherapy-induced CRS patent family.

The latest development follows patent grants in Australia in March 2026 and Canada in May 2026, further strengthening Poolbeg's expanding global intellectual property portfolio.

The patent covers the use of p38 MAPK inhibitors, including POLB 001, for the prevention of cancer immunotherapy-induced CRS and is supported by proprietary data generated by the company. Management believes the grant enhances the programme's competitive positioning as POLB 001 advances through clinical development.

Poolbeg is currently progressing its TOPICAL trial, with interim data expected later this summer. The company said the European patent grant is expected to increase the programme's attractiveness to potential partners while supporting its long-term commercial value.

Poolbeg Pharma Chief Executive Officer Jeremy Skillington said: "This decision to grant the European patent further strengthens our IP protection for POLB 001 in cancer immunotherapy-induced CRS. Europe represents one of the most strategically important pharmaceutical markets and this grant increases the commercial value of POLB 001 to potential partners at a critical stage in the programme's development."

View from Vox

While patent grants are rarely immediate share price drivers on their own, this award is strategically significant given the timing. Poolbeg is approaching a key clinical inflection point, with interim data from its TOPICAL trial expected later this summer, and securing protection in Europe strengthens the commercial foundations of the programme ahead of any future partnering discussions.

For investors, the focus now shifts back to clinical execution. Positive TOPICAL data remains the primary catalyst for POLB 001, but a strengthening patent portfolio provides additional support for the asset's potential value in future licensing or partnership negotiations.